1. Academic Validation
  2. Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa

Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa

  • RSC Med Chem. 2025 Aug 13. doi: 10.1039/d5md00393h.
Riccardo Di Leo 1 2 Enrico Crispino 1 Doretta Cuffaro 1 Giuseppantonio Maisetta 3 Andrea Bertacca 3 Marta Bianchi 3 Giovanna Batoni 3 Imin Wushur 4 Fatema Amatur Rahman 4 Jan-Olof Winberg 4 Ingebrigt Sylte 4 5 Armando Rossello 1 Elisa Nuti 1
Affiliations

Affiliations

  • 1 Department of Pharmacy, University of Pisa via Bonanno 6 56126 Pisa Italy elisa.nuti@unipi.it +39 0502219551.
  • 2 Institute of Clinical Physiology, National Research Council (CNR) via Moruzzi 1 56124 Pisa Italy.
  • 3 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa Via S. Zeno 37-39 56123 Pisa Italy.
  • 4 Department of Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway NO-9037 Tromsø Norway.
  • 5 Center for Research and Education, University Hospital of North Norway (UNN) Norway.
Abstract

The emergence of multidrug-resistant pathogens, particularly Pseudomonas aeruginosa, represents a global health concern. Among its major virulence factors, Elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate Bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of N-benzyloxy Amino Acid Derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound 12 as the most potent inhibitor (K i = 0.92 μM), exhibiting high selectivity for LasB over human Matrix Metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting Bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm Bacterial virulence rather than exerting bactericidal pressure.

Figures
Products